FINASTERIDE TOPICA VS ORALE con ANDREA MARLIANI

Main ideas / concepts conveyed

Purpose of finasteride and dosing

• Finasteride is described as a drug originally developed to treat benign prostatic hypertrophy (enlarged prostate), typically at 5 mg/day (sometimes 10 mg/day).
• For male androgenetic alopecia (pattern hair loss), the discussion frames it as being used at lower doses, commonly 1 mg/day.

Side effects: oral vs. topical, and the “nocebo” concept

• The speakers argue that at 1 mg/day (and even 0.5 mg/day) finasteride used for hair loss does not meaningfully increase side effects beyond what would be expected otherwise.
• They emphasize nocebo effects:
  • If patients receive placebo/empty tablets but are told they contain finasteride, they may still report side effects.
• They suggest side effects are influenced by the patient’s psychological state/personality.
• A caution is mentioned: finasteride should not be given to depressed individuals, because side effects may be more noticeable or amplified.

Fertility concerns

• A “real” but framed-as-limited issue is discussed: people trying to conceive soon may experience a possible slight decrease in male fertility.
• The effect is described as temporary:
  • Finasteride is said to clear from the blood after stopping, and
  • spermatogenesis takes ~3 months, so full recovery to maximum fertility may take time.
• Practical recommendation:
  • After long-term use, if someone wants to conceive, they should do a spermiogram first.
  • If results are normal/sufficient, conception is described as feasible.
• Timing and seasonal notes:
  • Spermiogram results can vary over time.
  • Fertility markers are said to be better in winter and worse in summer (lower sperm count and mobility in summer).

Post-finasteride syndrome (PFS) discussion

• The video addresses post-finasteride syndrome with a skeptical/critical stance:
  • It is suggested that PFS does not truly exist as a distinct phenomenon, or may instead reflect pre-existing depression/anxiety that becomes more apparent with/through finasteride.
• A hypothesized mechanism (not proven) is mentioned:
  • Finasteride blocks 5-alpha-reductase, which may affect neurohormone pathways related to mood/anxiety.
  • Small doses could theoretically worsen an existing anxiety-depressive disorder, but this is presented as unproven.

Potential regulatory/label changes

• Subtitles mention possible revision of package leaflet information.
• There is also discussion of a possible market withdrawal (rumor/concern), though the speaker notes prescription rules would remain complex.

Prescription constraints (Italy context)

• 1 mg finasteride for hair loss:
  • described as a non-repeatable medical prescription (harder to prescribe).
• 5 mg finasteride:
  • described as repeatably prescribed (prescription can be reused).

Topical finasteride vs. oral finasteride: effectiveness and delivery concerns

• Topical finasteride is described as being designed to avoid oral intake, but the delivery method is questioned.
• Delivery concern described:
  • Topical finasteride is delivered as a spray into a cone onto the scalp/hair.
  • Concern: much of the drug may remain on hair shafts rather than reaching the skin, reducing absorption.
• Absorption discussion:
  • Absorption estimates are described as theoretical, based on difficult experimental conditions (e.g., scarified skin and occlusion/plastic dressing).
  • The speaker argues real-world conditions are less favorable for absorption.
• Proposed alternative methodology:
  • The speaker suggests using a low-dose finasteride administered with a dropper, placing it directly on the skin to reduce waste left on hair.

Evidence quality and placebo effect in hair loss treatments

• The video claims studies on topical finasteride exist but may be biased and/or not well documented within trichology product effectiveness.
• Broader point:
  • Placebo effects can improve perceived and observed outcomes in hair treatments.
• Verification of true hair loss:
  • Doctors should verify whether the patient is truly losing hair, using genetic/family pattern context (e.g., father and maternal grandfather).
  • The predicted balding outcome is described as reflecting a family “average.”

Final preference stated

• One speaker explicitly prefers oral finasteride:
  • Claimed advantages include no side effects at 1 mg or less, and possibly effectiveness even at 0.5 mg/day.
• They also suggest topical finasteride may increase willingness/adherence because it is often presented as having fewer side effects, reducing patient anxiety.

---

Methodology / instructions presented (detailed bullet points)

Before starting finasteride (especially if aiming for conception)

• Get a baseline spermiogram to understand starting fertility status.
• Plan to repeat the spermiogram after ~1 year, since results can vary over time.
• Account for seasonal variation:
  • Expect sperm parameters to be better in winter and worse in summer.

If trying to conceive after prolonged finasteride use

• If someone has taken finasteride long-term (example: 10 years) and wants to conceive:
  • Do a spermiogram first.
  • If results are normal/sufficient, conception is described as feasible.

When topical finasteride is discussed

• Evaluate delivery efficiency:
  • Prefer methods that place drug on skin rather than leaving it on hair.
• Proposed improvement:
  • Use a dropper for direct skin application rather than a spray cone, which may waste product on hair.

Clinical reasoning for hair loss treatment

• Before treating, assess whether the patient is truly experiencing hair loss:
  • Compare family history (father’s hair status and maternal grandfather’s hair status).
  • Use genetics to infer likely eventual pattern and a baseline “target” level.

---

Speakers / sources featured (as identifiable from subtitles)

1. Dr. Andrea Marliani — guest; trichology expert; founder of Sitri (Italian Society of Trichology)
2. Dr. Guido Vido Trotter — guest; psychologist (40+ years of experience)
3. “Merc” / “the company” — mentioned as associated with studies about finasteride (exact full company name not clearly captured)
4. “Litte” — referenced as a source of studies comparing topical finasteride effectiveness (name unclear in subtitles; full reference not provided)
5. Dr. Dovidio Di Bari — mentioned as a colleague with 40–45 years of experience and work related to hair treatments